← 返回 Skills 市场
hanxueyuan

Exelixis

作者 hanxueyuan · GitHub ↗ · v1.0.0 · MIT-0
cross-platform ✓ 安全检测通过
73
总下载
0
收藏
0
当前安装
1
版本数
在 OpenClaw 中安装
/install exelixis
功能描述
Exelixis develops cabozantinib-based multi-kinase inhibitors for kidney, liver, and thyroid cancers, focusing on oncology combination therapies and pipeline...
使用说明 (SKILL.md)

Exelixis

历史时间线

  • 1994: Founded in Alameda, California
  • 2000s: Pioneers small-molecule kinase inhibitor discovery platform
  • 2012: FDA approves cabozantinib (Cometriq) for medullary thyroid cancer
  • 2016: Cabometyx approved for advanced renal cell carcinoma
  • 2019: HCC indication approved (liver cancer)
  • 2021: COSMIC-313 trial shows combination therapy benefit
  • 2023: Revenue $2.2B, expanding into new oncology indications
  • 2024: Pipeline expansion beyond cabozantinib

商业模式

Focused oncology company centered on cabozantinib (Cabometyx), a multi-kinase inhibitor targeting MET, VEGFR2, and AXL. Revenue from Cabometyx sales across kidney cancer, liver cancer, and thyroid cancer. Pipeline includes next-generation kinase inhibitors and combination therapies with immunotherapy.

护城河分析

Cabozantinib's multi-kinase targeting creates broader efficacy than single-target competitors. Expanded label across three cancer types diversifies revenue. Long patent life with potential extensions through combination indications.

关键数据

  • Founded: 1994, Alameda, California
  • Revenue 2023: ~$2.2B
  • Employees: ~800
  • Flagship Drug: Cabometyx (cabozantinib)
  • Indications: Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Cancer

有趣事实

  • Exelixis's name comes from 'helix' (DNA) and the Greek prefix for 'evolution' — reflecting their focus on evolving cancer treatments.
  • Cabozantinib was originally developed for thyroid cancer but found its biggest commercial success in kidney and liver cancer — a classic example of drug repurposing.
安全使用建议
This skill is informational only and does not request credentials or install software, so it appears safe to add from a system-privilege perspective. However, the skill's source/homepage is unknown and SKILL.md is a static summary — verify any clinical, financial, or regulatory claims against authoritative sources (company filings, peer-reviewed literature, FDA notices) before using the information for decisions, and do not treat it as medical advice.
功能分析
Type: OpenClaw Skill Name: exelixis Version: 1.0.0 The skill bundle contains purely informational content regarding Exelixis, a biopharmaceutical company. There is no executable code, no network requests, and no prompt injection attempts within SKILL.md or _meta.json. The content is strictly educational and aligns with its stated purpose.
能力评估
✓ Purpose & Capability
The skill's name and description match the SKILL.md content (company background, timeline, business analysis). It does not request unrelated resources or capabilities. Note: the skill's source/homepage is unknown, which limits verifiability but does not create an internal coherence problem.
✓ Instruction Scope
SKILL.md contains only static informational content and 'read_when' guidance for when to use it. It does not instruct the agent to read system files, access environment variables, or send data externally.
✓ Install Mechanism
No install spec and no code files — instruction-only. There is nothing written to disk or downloaded during install.
✓ Credentials
The skill declares no required environment variables, credentials, or config paths; requested privileges are minimal and proportional to an informational skill.
✓ Persistence & Privilege
always is false and the skill does not request persistent presence or modify other skills. disable-model-invocation is false (normal); autonomous invocation is allowed by platform default but this skill's read-only nature keeps risk low.
如何使用
  1. 确保已安装 OpenClaw（本地或 Docker 部署）
  2. 在对话框中输入安装命令：/install exelixis
  3. 安装完成后，直接呼叫该 Skill 的名称或使用 /exelixis 触发
  4. 根据 Skill 的参数说明提供必要输入，即可获得结构化输出
版本历史
v1.0.0
Exelixis skill initial release: - Provides an overview of Exelixis, a biopharmaceutical company focused on oncology. - Includes a company history timeline highlighting major drug approvals and milestones. - Outlines the business model, emphasizing Cabometyx and combination therapies. - Features a moat analysis summarizing competitive advantages. - Lists key facts and interesting insights about Exelixis and its flagship drug.
元数据
Slug exelixis
版本 1.0.0
许可证 MIT-0
累计安装 0
当前安装数 0
历史版本数 1
常见问题

Exelixis 是什么？

Exelixis develops cabozantinib-based multi-kinase inhibitors for kidney, liver, and thyroid cancers, focusing on oncology combination therapies and pipeline... 它是一个面向 Claude Code / OpenClaw 的 AI Agent Skill 插件，目前累计下载 73 次。

如何安装 Exelixis？

在 OpenClaw 或 Claude Code 对话框中运行命令「/install exelixis」即可一键安装，无需额外配置。

Exelixis 是免费的吗？

是的，Exelixis 完全免费，采用 MIT-0 许可证，可自由下载、安装和使用。

Exelixis 支持哪些平台？

Exelixis 跨平台运行，可在任意部署了 OpenClaw / Claude Code 的环境中使用（cross-platform）。

谁开发了 Exelixis？

由 hanxueyuan（@hanxueyuan）开发并维护，当前版本 v1.0.0。

推荐 Skills
self-improving agent
Captures learnings, errors, and corrections to enable continuous improvement. Use when: (1) A command or operation fails unexpectedly, (2) User corrects Clau...
⬇ 463283 · by pskoett
Skill Vetter
Security-first skill vetting for AI agents. Use before installing any skill from ClawdHub, GitHub, or other sources. Checks for red flags, permission scope, and suspicious patterns.
⬇ 259410 · by spclaudehome
Polymarket
Query Polymarket prediction markets. Check odds, find trending markets, search events, track price movements.
⬇ 232503 · by joelchance
Self-Improving + Proactive Agent
Self-reflection + Self-criticism + Self-learning + Self-organizing memory. Agent evaluates its own work, catches mistakes, and improves permanently. Use when...
⬇ 200423 · by ivangdavila
Github
Interact with GitHub using the `gh` CLI. Use `gh issue`, `gh pr`, `gh run`, and `gh api` for issues, PRs, CI runs, and advanced queries.
⬇ 191115 · by steipete
ontology
Typed knowledge graph for structured agent memory and composable skills. Use when creating/querying entities (Person, Project, Task, Event, Document), linkin...
⬇ 190156 · by oswalpalash

💬 留言讨论